News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.
The result could reshape Moderna's post-vaccine growth story
A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss.
By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its
On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.
By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh
Shares of US vaccine-maker Moderna soared 60 per cent in pre-market trading after the company reported successful results for a melanoma cancer...
An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said. Shares in Moderna jumped about 10% premarket, while Merck also climbed around 6%.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.
With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.
Oncology and animal health drove $16.6B revenue growth amid upcoming patent expirations.
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year
Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
Merck KGaA (ETR:MRK) reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share. Group net sales rose 3.4% year over year to €5.434 billion. Organic sales g
Moby summary of Arcus Biosciences, Inc.'s Q2 2026 earnings call
Investing.com-- Merck clocked a stronger second-quarter adjusted profit on Tuesday, aided by strong performances in its life science and electronics divisions, with the company also raising its annual profit outlook.
The group pointed to stronger demand in the life-science and electronics markets and resilience in its healthcare operations.
A new round of strong earnings reports powered the Dow Jones Industrial Average to a fresh high on Wednesday, underscoring how surging profits are underpinning the stock-market rally. Upbeat reports from Amgen Walt Disney and Merck helped send the blue-chip index 0.5%, or 263 points, higher to 54349. The Dow industrials have now climbed for five straight sessions, notching three straight records and a 5.3% gain in their best such run since the volatile days of the April 2025 tariff panic.
Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.